Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med.

Enviado por remote_content el Lun, 21/10/2024 - 08:34

Enfermedades infecciosas

WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Alvarez-Moreno CA, Bravo J, Saavedra C, Chacon J, Zuluaga I, et al, 2/12/2020.

BACKGROUND
World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19).

CONCLUSIONS
These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.)

Read full article

Investigación y educación

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med.

Artículos que te pueden interesar

Genotypic, proteomic, and phenotypic approaches to decipher the response to caspofungin and calcineurin inhibitors in clinical isolates of echinocandin-resistant Candida glabrata. J Antimicrob Chemother.

Implications of Antibiotic Use During the COVID-19 Pandemic: The Example of Associated Antimicrobial Resistance in Latin America. Antibiotics

A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): A consensus of Latin American experts. Int J Infect Dis.